Page 264 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHAPTEr 16 Helper T-Cell Subsets and Control of the Inflammatory Response 245

11. Blattman JN, Antia R, Sourdive DJ, et al. Estimating the precursor
SUMMARY OF THERAPEUTIC REGULATION OF frequency of naive antigen-specific CD8 T cells. J Exp Med
T-CELL RESPONSES FOR TREATMENT OF 12. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues
2002;195:657–64.
IMMUNE-MEDIATED DISEASES and sites of inflammation. Nat Rev Immunol 2004;4:325–35.
13. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in
ON THE HOrIZON secondary lymphoid organs. Annu Rev Immunol 2005;23:127–59.
14. Rebenko-Moll NM, Liu L, Cardona A, et al. Chemokines, mononuclear
• Development of effective techniques to identify antigens targeted in cells and the nervous system: heaven (or hell) is in the details. Curr Opin
organ-specific autoimmune and allergic diseases and in transplant Immunol 2006;18:683–9.
rejection 15. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space
• Development and implementation of an effective tolerance-inducing to a sense of place. Nat Rev Immunol 2009;9:823–32.
strategy capable of regulating T-cell responses in an antigen-specific
manner 16. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine
• Identification of tolerance-specific biomarkers or assays to clearly helper T cell clone. I. Definition according to profiles of lymphokine
delineate successful therapy of inflammatory diseases activities and secreted proteins. J Immunol 1986;136:2348–57.
17. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by
networks of cytokines and transcription factors. Immunol Rev
T cell–mediated inflammation is central to immune-mediated 2010;238:247–62.
diseases. Many of the most effective techniques to control inflam- 18. Coffman RL, Lebman DA, Rothman P. Mechanism and regulation of
mation are aimed at the processes of T-cell activation, differentia- immunoglobulin isotype switching. Adv Immunol 1993;54:229–70.
tion, trafficking, or effector functions (Fig. 16.5). Among many 19. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and
potential approaches currently being employed or in development, amplified? Nat Rev Immunol 2010;10:225–35.
include the following: (i) blockade of appropriate costimulatory 20. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid
signals or intracellular signaling molecules to prevent T-cell proliferation, apoptosis and differentiation. Nat Rev Immunol
activation (i.e., FK504) or to promote ongoing effector inflam- 2005;5:688–98.
matory responses (i.e., anti-PD-L1); (ii) preventing recruitment 21. Dong C. Diversification of T-helper-cell lineages: finding the family root
of IL-17-producing cells. Nat Rev Immunol 2006;6:329–33.
of effector T cells into inflammatory sites by targeting pathways 22. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology
required for cellular recruitment (i.e., VLA-4); (iii) neutralizing 2009;127:450–8.
the cytokines that promote T-effector differentiation (e.g., IL-6, 23. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct
IL-12, or IL-23); (iv) blocking proinflammatory cytokines (e.g., human T cell subset involved in epidermal immunity and remodeling. J
IFN-γ, IL-17, GM-CSF, or TNF-α) and other effector molecules Clin Invest 2009;119:3573–85.
(e.g., iNOS, reactive oxygen intermediates, etc.) involved in the 24. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells
effector limb of destructive inflammatory processes; (v) the use — ex vivo expansion and therapeutic potential. Semin Immunol
of regulatory cytokines, such as TGF-β, IL-4, or IL-10 to regulate 2006;18:103–10.
proinflammatory responses; and (vi) in vivo induction of Treg 25. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting
activity using tolerance strategies or ex vivo expansion and type 1 regulatory T cells in rodents and humans. Immunol Rev
administration of protective or regulatory T-cell subsets. 2006;212:28–50.
26. Byrne P, McGuirk P, Todryk S, et al. Depletion of NK cells results in
Please check your eBook at https://expertconsult.inkling.com/ disseminating lethal infection with Bordetella pertussis associated with a
for self-assessment questions. See inside cover for registration reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1
details. cells. Eur J Immunol 2004;34:2579–88.
27. Nutt SL, Tarlinton DM. Germinal center B and follicular helper T cells:
REFERENCES siblings, cousins or just good friends? Nat Immunol 2011;12:472–7.
28. Crotty S. T follicular helper cell differentiation, function, and roles in
1. Fischer A. Recent advances in understanding the pathophysiology of disease. Immunity 2014;41:529–42.
primary T cell immunodeficiencies. Trends Mol Med 2015;21:408–16. 29. Ma CS, Uzel G, Tangye SG. Human T follicular helper cells in primary
2. Bussone G, Mouthon L. Autoimmune manifestations in primary immune immunodeficiencies. Curr Opin Pediatr 2014;26:720–6.
deficiencies. Autoimmun Rev 2009;8:332–6. 30. Lanzavecchia A, Sallusto F. Understanding the generation and function of
3. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev memory T cell subsets. Curr Opin Immunol 2005;17:326–32.
Immunol 2009;27:591–619. 31. Carbone FR. Tissue-resident memory T cells and fixed immune
4. Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity surveillance in nonlymphoid organs. J Immunol 2015;195:17–22.
and adaptation of the immunological synapse. Nat Rev Immunol 32. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and
2005;5:532–45. plasticity of helper CD4+ T cells. Science 2010;327:1098–102.
5. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation 33. Roberts AI, Devadas S, Zhang X, et al. The role of activation-induced cell
in dendritic cells. Curr Opin Immunol 2010;22:124–30. death in the differentiation of T-helper-cell subsets. Immunol Res
6. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph 2003;28:285–93.
nodes through lymphatic vessels. Nat Rev Immunol 2005;5:617–28. 34. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point
7. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by of view. Immunol Res 2003;28:241–53.
dendritic cells in lymph nodes occurs in three distinct phases. Nature 35. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological
2004;427:154–9. tolerance. Trends Immunol 2006;27:195–201.
8. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic 36. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T
responses. Immunol Rev 2011;241:206–27. cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480–90.
9. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions 37. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with
of mTOR inhibition. Nat Rev Immunol 2009;9:324–37. divergent functions. Nat Rev Immunol 2005;5:521–31.
10. Quezada SA, Peggs KS, Simpson TR, et al. Shifting the equilibrium in 38. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta
cancer immunoediting: from tumor tolerance to eradication. Immunol regulation of immune responses. Annu Rev Immunol 2006;24:
Rev 2011;241:104–18. 99–146.